Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Cisplatin ³»¼º ¼Ò¼¼Æ÷Æó¾Ï ¼¼Æ÷¿¡¼­ Neuron Specific Enolase ¹× Creatine Kinase-BBÀÇ ¼¼Æ÷³» ³óµµÀÇ º¯È­ Altered Production of Neuron Specific Enolase and Creatine Kinase-BB in Cisplatin-Resistant Small Cell Lung Cancer Cells

´ëÇѾÏÇÐȸÁö 1988³â 20±Ç 1È£ p.43 ~ 46
¼Ò¼Ó »ó¼¼Á¤º¸
Hong, Weon-Seon/È«¿ø¼± Kato, Kanefusa/Takahashi, Hidenobu/Sasaki, Yasutsuna/Saijo, Nagahiro/°¡³×ÈÄ»ç °¡¶Ç/È÷µ¥³ëºÎ ´ÙÄ«ÇϽÃ/¾ß¼öÂ곪 »ç»ç³¢/³ª°¡È÷·Î »çÀÌÁ¶

Abstract

Neuron Specfic Enolase(NSE)¿Í Creatine Kinase BB(CK-BB)¸¦ Àΰ£ ¼Ò¼¼Æ÷Æó¾Ï¼¼Æ÷ÀÎ H69(classic type)°ú 3°³ÀÇ cisplatin ³»¼º ¼¼Æ÷(H69/0.1,H69/0.2¿Í H69/0.4)¿¡¼­ ´Ü¼¼Æ÷ Ç×ü¸¦ ÀÌ¿ëÇÑ È¿¼Ò ¸é¿ª ÃøÁ¤¹ýÀ¸·Î ÃøÁ¤ÇÏ¿´´Ù.H69/0.1(0.1¥ìg/mlÀÇ cisplatinÀÌ Ã³¸¶µÈ ¹è¾ç¾×¿¡¼­ ¼ºÀå °¡´ÉÇÑ H69¼¼Æ÷)H69/0.2¿ÍH69/0.4´Â °¢°¢ Soft agar colony assay¿¡¼­ H69¿¡ºñÇÏ¿© IC_50·Î ºñ±³ÇÏ¿´À» ¶§ 2.4¹è,4.8¹è, 25.6¹èÀdz»¼ºÀ» º¸¿´´Ù.¾àÇÑ ³»¼º¼¼Æ÷ÀÎ H69/0.1°ú H69/0.2¿¡¼­ÀÇ ¼¼Æ÷³» NSE´Â H69¿Í ºñ½ÁÇÏ¿´À¸³ª °­ÇÑ ³»¼º¼¼Æ÷ÀÎ H69/0.4¿¡¼­´Â 58%·Î °¨¼ÒÇÏ¿´´Ù. CK-BBÀÇ ¼¼Æ÷³» ³óµµ´Â ³»¼ºÀÇ Á¤µµ°¡ Áõ°¡ÇÒ¼ö·Ï Áõ°¡ÇÏ¿´À¸¸ç(r=0.98,¤Ä<0.02),H69/0.4¿¡¼­´Â H69º¸´Ù 320%Áõ°¡¸¦ º¸¿´´Ù. ÀÌ»óÀÇ°á°ú¿¡¼­ H69/0.4´Â ¸ð¼¼Æ÷ÀÎ H69°ú´Â »ý¹°ÇÐÀû Ư¼ºÀÌ ´Ù¸¥ Áý´ÜÀÇ ¼¼Æ÷ÀÓÀ» ½Ã»çÇÏ¿´´Ù.
We have previously demonstrated that biologic properties of cisplatin (CDDP)-resistant H69 sub-lines were different from those of parent H69, human small cell lung cancer (SCLC) cell line^(1)). The biological properties of SCLC have been shown to be similar to those of amine precursor uptake and decarboxylation (APUD) cells, characterized by the presence of neurosecretory granules and the production of various hormones and peptides^(2)). Neuron specific enolase (NSE) and creatine kinase-BB (CKBB) have been considered to be some of the biomarkers for SCLC^(34)) . To investigate whether the production of these two enzymes changes in the resistant sublines, intracellular concentrations of NSE and CK-BB were determined in the H69 parent cell line and its resistant sublines.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS